ARWR · NASDAQ
Arrowhead Pharmaceuticals (ARWR) Stock Price & Fundamentals
Arrowhead Pharmaceuticals (ARWR) closed at $894.05 on Oct 9, 2026, down 0.80% from the previous close of $901.24.
Share price, past year
1Y +50.12%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $894.05 |
| Sep 30, 2026 | $911.07 |
| Aug 31, 2026 | $829.85 |
| Jul 31, 2026 | $814.49 |
| Jun 30, 2026 | $774.49 |
| May 29, 2026 | $714.35 |
| Apr 30, 2026 | $702.20 |
| Mar 31, 2026 | $700.03 |
| Feb 27, 2026 | $662.74 |
| Jan 30, 2026 | $681.96 |
| Dec 31, 2025 | $688.90 |
| Nov 28, 2025 | $635.94 |
| Oct 31, 2025 | $614.78 |
Key statistics
- Market cap
- $126.18B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.18
- Revenue (TTM)
- $669.50M
- Net income (TTM)
- −$319.95M
- Shares outstanding
- 141.1M
- Dividend yield
- —
- 52-week range
- $591.01 – $926.39
Arrowhead Pharmaceuticals's market cap is $126.18B, based on a share price of $894.05 and 141.1M shares outstanding as of Jun 30, 2026.
Financials
Arrowhead Pharmaceuticals reported revenue of $829.45M for fiscal 2025, up 23,258.15% from fiscal 2024.
Arrowhead Pharmaceuticals reported a net loss of $1.63M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Sep 30, 2025 | $829.45M | +23,258.2% | −$1.63M | −0.2% | −$0.01 | $156.89M |
| FY2024ended Sep 30, 2024 | $3.55M | −98.5% | −$599.49M | −16,882.4% | −$5.00 | −$604.32M |
| FY2023ended Sep 30, 2023 | $240.74M | −1.0% | −$205.28M | −85.3% | −$1.92 | −$330.63M |
| FY2022ended Sep 30, 2022 | $243.23M | +75.9% | −$176.06M | −72.4% | −$1.67 | −$188.91M |
| FY2021ended Sep 30, 2021 | $138.29M | +57.2% | −$140.85M | −101.9% | −$1.36 | $147.75M |
| FY2020ended Sep 30, 2020 | $87.99M | −47.9% | −$84.55M | −96.1% | −$0.84 | −$107.75M |
| FY2019ended Sep 30, 2019 | $168.80M | +945.7% | $67.98M | 40.3% | $0.69 | $161.03M |
| FY2018ended Sep 30, 2018 | $16.14M | −48.6% | −$54.45M | −337.3% | −$0.65 | −$48.64M |
| FY2017ended Sep 30, 2017 | $31.41M | +19,736.5% | −$34.38M | −109.5% | −$0.47 | −$31.86M |
| FY2016ended Sep 30, 2016 | $158.33K | — | −$81.72M | −51,614.6% | −$1.34 | −$68.29M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2026ended Jun 30, 2026 | $75.25M | −$194.28M | −$1.36 |
| Q2 FY2026ended Mar 31, 2026 | $73.74M | −$132.73M | −$0.93 |
| Q1 FY2026ended Dec 31, 2025 | $264.03M | $30.81M | $0.22 |
| Q4 FY2025ended Sep 30, 2025 | $256.47M | −$23.75M | −$0.11 |
| Q3 FY2025ended Jun 30, 2025 | $27.77M | −$175.24M | −$1.26 |
| Q2 FY2025ended Mar 31, 2025 | $542.71M | $370.45M | $2.75 |
| Q1 FY2025ended Dec 31, 2024 | $2.50M | −$173.09M | −$1.39 |
| Q4 FY2024ended Sep 30, 2024 | $0.00 | −$170.54M | −$1.36 |
Company profile
- Name
- Arrowhead Pharmaceuticals, Inc.
- Ticker
- ARWR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 177 E Colorado Blvd, Suite 700, Pasadena, CA 91105
- Incorporated in
- DE
- Fiscal year ends
- September
- SEC CIK
- 0000879407
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jun 16, 2026
- May 7, 2026
- May 7, 2026
- Mar 20, 2026
- Feb 5, 2026
- Feb 5, 2026
Frequently asked questions
What is Arrowhead Pharmaceuticals's stock price?
Arrowhead Pharmaceuticals (ARWR) closed at $894.05 on Oct 9, 2026, down 0.80% from the previous close of $901.24.
What is Arrowhead Pharmaceuticals's market cap?
Arrowhead Pharmaceuticals's market cap is $126.18B, based on a share price of $894.05 and 141.1M shares outstanding as of Jun 30, 2026.
How much revenue does Arrowhead Pharmaceuticals make?
Arrowhead Pharmaceuticals reported revenue of $829.45M for fiscal 2025, up 23,258.15% from fiscal 2024.
Does Arrowhead Pharmaceuticals pay a dividend?
Arrowhead Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Arrowhead Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures